Neuronetics Net Common Equity Issued/Repurchased 2017-2024 | STIM
Neuronetics net common equity issued/repurchased from 2017 to 2024. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
| Neuronetics Annual Net Common Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $3 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $83 |
| 2020 | $1 |
| 2019 | $2 |
| 2018 | $101 |
| 2017 | $0 |
| 2016 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.301B | $0.075B |
| Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. | |||